Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids

Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids

Higher global prevalence of non-alcoholic fatty liver disease (NAFLD) is associated with obesity, steatosis, and insulin resistance (IR), and often progresses to steatohepatitis (NASH). Even after more than twenty years of research, there is still no FDA approved therapy for the treatment of fatty l...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Soumalya Sarkar, Deepika Kumari, Sonu Kumar Gupta, Vipin Sharma, Sumedha Mukhi, Parul Kamboj, Vedula Sasibhushan, Rajiva Kumar Rai, Sastry Lakshminarayana Jatavallabhula, Dinesh Mahajan, Yashwant Kumar, Ajay Kumar, Madhu Dikshit
Format: article
Langue:EN
Publié: Elsevier 2021
Sujets:
High fat high fructose
Non-alcoholic fatty liver disease
Insulin resistance
Lipidomics
Saroglitazar
Hepano
Therapeutics. Pharmacology
RM1-950
Accès en ligne:https://doaj.org/article/34389400b90547f6a85e0882da0b10a7
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/34389400b90547f6a85e0882da0b10a7

Documents similaires